FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy

Neuropharmacology

Volumn 55, Issue 7, 2008, Pages 1226-1230

  Yamazaki, Shunji ^a   Yamaji, Takayuki ^a   Murai, Nobuhito ^a   Yamamoto, Hiroko ^a   Price, Raymond D ^a   Matsuoka, Nobuya ^a   Mutoh, Seitaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Allodynia; Diabetic neuropathy; FK1706; Immunophilin; Nerve fiber; Pain

Indexed keywords

1,14 DIHYDROXY 12 [2 (4 HYDROXY 3 METHOXYCYCLOHEXYL) 1 METHYLVINYL] 23,25 DIMETHOXY 13,19,21,27 TETRAMETHYL 17 (2 OXOPROPYL) 11,28 DIOXA 4 AZATRICYCLO[22.3.1.0 4.9]OCTACOS 18 ENE 2,3,10,16 TETRONE; FK 1706; GABAPENTIN; IMMUNOPHILIN; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG POTENTIATION; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; MALE; NERVE FIBER; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TREATMENT OUTCOME;

AMINES; ANALGESICS; ANIMALS; CYCLOHEXANECARBOXYLIC ACIDS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-AMINOBUTYRIC ACID; IMMUNOHISTOCHEMISTRY; IMMUNOPHILINS; LIGANDS; MALE; PAIN; PAIN MEASUREMENT; PHYSICAL STIMULATION; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS;

EID: 54049089162     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.07.048     Document Type: Article

References (41)

1. Apfel S.C. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold?. Int. Rev. Neurobiol. 50 (2002) 393-413
2. Atherton D.D., Facer P., Roberts K.M., Misra V.P., Chizh B.A., Bountra C., and Anand P. Use of the novel Contact Heat Evoked Potential Stimulator (CHEPS) for the assessment of small fibre neuropathy: correlations with skin flare responses and intra-epidermal nerve fibre counts. BMC Neurol. 7 (2007) 21
3. Backonja M., Beydoun A., Edwards K.R., Schwartz S.L., Fonseca V., Hes M., LaMoreaux L., and Garofalo E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280 (1998) 1831-1836
4. Bianchi R., Buyukakilli B., Brines M., Savino C., Cavaletti G., Oggioni N., Lauria G., Borgna M., Lombardi R., Cimen B., Comelekoglu U., Kanik A., Tataroglu C., Cerami A., and Ghezzi P. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 823-828
5. Calcutt N.A., Jorge M.C., Yaksh T.L., and Chaplan S.R. Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain 68 (1996) 293-299
6. Calcutt N.A., Muir D., Powell H.C., and Mizisin A.P. Reduced ciliary neuronotrophic factor-like activity in nerves from diabetic or galactose-fed rats. Brain Res. 575 (1992) 320-324
7. Costantini L.C., Chaturvedi P., Armistead D.M., McCaffrey P.G., Deacon T.W., and Isacson O. A novel immunophilin ligand: distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinson's disease. Neurobiol. Dis. 5 (1998) 97-106
8. Courteix C., Bardin M., Chantelauze C., Lavarenne J., and Eschalier A. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain 57 (1994) 153-160
9. Courteix C., Eschalier A., and Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 53 (1993) 81-88
10. Dawson T.M., Steiner J.P., Lyons W.E., Fotuhi M., Blue M., and Snyder S.H. The immunophilins, FK506 binding protein and cyclophilin are discretely localized in the brain: relationship to calcineurin. Neuroscience 62 (1994) 569-580
11. Dyck P.J., Kratz K.M., Karnes J.L., Litchy W.J., Klein R., Pach J.M., Wilson D.M., O'Brien P.C., Melton III L.J., and Service F.J. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 43 (1993) 817-824
12. Field M.J., McCleary S., Hughes J., and Singh L. Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain 80 (1999) 391-398
13. Fischer G., Wittmann-Liebold B., Lang K., Kiefhaber T., and Schmid F.X. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 337 (1989) 476-478
14. Gee N.S., Brown J.P., Dissanayake V.U.K., Offord J., Thurlow R., and Woodruff G.N. The novel anticonvulsant drug, Gabapentin (Neurontin), binds to the ad subunit of a calcium channel. J. Biol. Chem. 271 (1996) 5768-5776
15. Gimbel J.S., Richards P., and Portenoy R.K. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 60 (2003) 927-934
16. Goldstein D.J., Lu Y., Detke M.J., Lee T.C., and Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116 (2005) 109-118
17. Griffith J.P., Kim J.L., Kim E.E., Sintchak M.D., Thomson J.A., Fitzgibbon M.J., Fleming M.A., Caron P.R., Hsiao K., and Navia M.A. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 82 (1995) 507-522
18. Harding M.W., Galat A., Uehling D.E., and Schreiber S.L. A receptor for the immuno-suppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 341 (1989) 758-760
19. Hayashi N., Minor T.X., Carrion R., Price R., Nunes L., and Lue T.F. The effect of FK1706 on erectile function following bilateral cavernous nerve crush injury in a rat model. J. Urol. 176 (2006) 824-829
20. Kalichman M.W., Powell H.C., and Mizisin A.P. Reactive, degenerative, and proliferative Schwann cell responses in experimental galactose and human diabetic neuropathy. Acta Neuropathol. 95 (1998) 47-56
21. Kiguchi S., Imamura T., Ichikawa K., and Kojima M. Oxcarbazepine antinociception in animals with inflammatory pain or painful diabetic neuropathy. Clin. Exp. Pharmacol. Physiol. 31 (2004) 57-64
22. Lauria G., Lombardi R., Borgna M., Penza P., Bianchi R., Savino C., Canta A., Nicolini G., Marmiroli P., and Cavaletti G. Intraepidermal nerve fiber density in rat foot pad: neuropathologic-neurophysiologic correlation. J. Peripher. Nerv. Syst. 10 (2005) 202-208
23. Leinninger G.M., Vincent A.M., and Feldman E.L. The role of growth factors in diabetic peripheral neuropathy. J. Peripher. Nerv. Syst. 9 (2004) 26-53
24. Lyons W.E., Steiner J.P., Snyder S.H., and Dawson T.M. Neuronal regeneration enhances the expression of the immunophilin FKBP-12. J. Neurosci. 15 (1995) 2985-2994
25. Madsen J.R., MacDonald P., Irwin N., Goldberg D.E., Yao G.L., Meiri K.F., Rimm I.J., Stieg P.E., and Benowitz L.I. Tacrolimus (FK506) increases neuronal expression of GAP-43 and improves functional recovery after spinal cord injury in rats. Exp. Neurol. 154 (1998) 673-683
26. Max M.B., Culnane M., Schafer S.C., Gracely R.H., Walther D.J., Smoller B., and Dubner R. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 37 (1987) 589-596
27. McCarthy B.G., Hsieh S.T., Stocks A., Hauer P., Macko C., Cornblath D.R., Griffin J.W., and McArthur J.C. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 45 (1995) 1848-1855
28. Nelson K.A., Park K.M., Robinovitz E., Tsigos C., and Max M.B. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 48 (1997) 1212-1218
29. Oskarsson P., Ljunggren J.G., and Lins P.E. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group. Diabetes Care 20 (1997) 1594-1597
30. Price R.D., Yamaji T., and Matsuoka N. FK506 potentiates NGF-induced neurite outgrowth via the Ras/Raf/MAP kinase pathway. Br. J. Pharmacol. 140 (2003) 825-829
31. Price R.D., Yamaji T., Yamamoto H., Higashi Y., Hanaoka K., Yamazaki S., Ishiye M., Aramori I., Matsuoka N., Mutoh S., Yanagihara T., and Gold B.G. FK1706, a novel non-immunosuppressive immunophilin: neurotrophic activity and mechanism of action. Eur. J. Pharmacol. 509 (2005) 11-19
32. Quattrini C., Jeziorska M., Boulton A.J., and Malik R.A. Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy. Diabetes Care 31 (2008) 140-145
33. Rakieten N., Rakieten M.L., and Nadkarni M.R. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother. Rep. 29 (1963) 91-98
34. Sezen S.F., Hoke A., Burnett A.L., and Snyder S.H. Immunophilin ligand FK506 is neuroprotective for penile innervation. Nat. Med. 7 (2001) 1073-1074
35. Sharkey J., and Butcher S.P. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature 371 (1994) 336-339
36. Siekierka J.J., Hung S.H., Poe M., Lin C.S., and Sigal N.H. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 341 (1989) 755-757
37. Small S.L., Fukui M.B., Bramblett G.T., and Eidelman B.H. Immunosuppression-induced leukoencephalopathy from tacrolimus (FK506). Ann. Neurol. 40 (1996) 575-580
38. Steiner J.P., Connolly M.A., Valentine H.L., Hamilton G.S., Dawson T.M., Hester L., and Snyder S.H. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nat. Med. 3 (1997) 421-428
39. Takahashi N., Hayano T., and Suzuki M. Peptidyl-prolyl cis-trans isomerase is the cyclosporine A-binding protein cyclophilin. Nature 337 (1989) 473-475
40. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 (1993) 977-986
41. Wong M.C., Chung J.W., and Wong T.K. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ 335 (2007) 87